Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Radiopharm Theranostics Limited ( (AU:RAD) ).
Radiopharm Theranostics announced its fiscal year 2025 financial results and provided a business update, highlighting significant progress in its clinical programs. Key achievements include the FDA’s Fast Track Designation for RAD101, DSMC approval for higher dosing of RAD204, and advancements in clinical trials for RAD202 and RAD204. These developments underscore the company’s commitment to transforming cancer care through precise, targeted radiopharmaceutical solutions.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need.
Average Trading Volume: 2,230,544
Technical Sentiment Signal: Sell
Current Market Cap: A$54.39M
Learn more about RAD stock on TipRanks’ Stock Analysis page.